Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

• Published in: The Journal of infectious diseases Vol. 207; no. 5; pp. 740 - 748
• Main Authors: Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.03.2013
• Subjects: Adult; Aged; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacology; Antiretroviral Therapy, Highly Active - methods; Biological and medical sciences; Drug Resistance, Viral; Female; Fundamental and applied biological sciences. Psychology; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - pharmacology; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - isolation & purification; Human immunodeficiency virus 1; Human viral diseases; Humans; Infectious diseases; Major and Brief Reports; MAJOR ARTICLES AND BRIEF REPORTS; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Pilot Projects; Plasma - virology; Pyrrolidinones - pharmacology; Raltegravir Potassium; RNA, Viral - blood; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Virology; Young Adult; Immunopathology; Antiretroviral agent; HIV-1 virus; Retroviridae; AIDS; Immune deficiency; Lentivirus; Virus; Infection; Resistance; Integrase inhibitor; Treatment; Efficiency; Viral disease; Antiviral; Human immunodeficiency virus; Raltegravir

Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL re...